Have you been eager to see how Ventas, Inc. (VTR - Free Report) performed in Q2 in comparison with the market expectations? Let’s quickly scan through the key facts from this Chicago, IL-based healthcare real estate investment trust (REIT) earnings release this morning:
A FFO Beat
Ventas came out with normalized funds from operations (FFO) per share of $1.08, beating the Zacks Consensus Estimate of $1.02.
Higher revenues were primarily responsible for this FFO beat.
How Was the Earnings Surprise Trend?
Ventas has a mixed surprise history. Before posting a FFO beat in Q2, the company delivered positive surprises in one of the trailing four quarters, met in other two and missed in another, resulting in an average negative surprise of 1.00%. This is depicted in the graph below:
Revenues Came In Higher Than Expected
Ventas posted revenues of $942.3 million, which beat the Zacks Consensus Estimate of $918.7 million. Further, it compared favorably with the year-ago number of $895.5 million.
Key Developments to Note
Ventas improved its 2018 normalized FFO per share outlook and expects it in the range of $4.02-$4.07. The company expects same-store cash net operating income growth to be 0.75-1.5% in 2018.
What Zacks Rank Says
Ventas has a Zacks Rank #3 (Hold). However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change.
(You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.)
Check back later for our full write up on this VTR earnings report!
Note: Anything related to earnings presented in this write-up represent funds from operations (FFO) — a widely used metric to gauge the performance of REITs.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Have you been eager to see how Ventas, Inc. (VTR - Free Report) performed in Q2 in comparison with the market expectations? Let’s quickly scan through the key facts from this Chicago, IL-based healthcare real estate investment trust (REIT) earnings release this morning:
A FFO Beat
Ventas came out with normalized funds from operations (FFO) per share of $1.08, beating the Zacks Consensus Estimate of $1.02.
Higher revenues were primarily responsible for this FFO beat.
How Was the Earnings Surprise Trend?
Ventas has a mixed surprise history. Before posting a FFO beat in Q2, the company delivered positive surprises in one of the trailing four quarters, met in other two and missed in another, resulting in an average negative surprise of 1.00%. This is depicted in the graph below:
Revenues Came In Higher Than Expected
Ventas posted revenues of $942.3 million, which beat the Zacks Consensus Estimate of $918.7 million. Further, it compared favorably with the year-ago number of $895.5 million.
Key Developments to Note
Ventas improved its 2018 normalized FFO per share outlook and expects it in the range of $4.02-$4.07. The company expects same-store cash net operating income growth to be 0.75-1.5% in 2018.
What Zacks Rank Says
Ventas has a Zacks Rank #3 (Hold). However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change.
(You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.)
Check back later for our full write up on this VTR earnings report!
Note: Anything related to earnings presented in this write-up represent funds from operations (FFO) — a widely used metric to gauge the performance of REITs.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on VTR - FREE